The benefits of Nd:YAG laser in the treatment of gum disease in an adult population

Adjunctive Nd:YAG laser irradiation in the treatment of stage III/IV periodontitis. A 12-month, randomized, controlled trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN26692900

Enrollment

Registered

2022-06-09

Start date

2015-11-24

Completion date

Unknown

Last updated

2023-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adjunctive Nd:YAG laser in non-surgical periodontal therapy Oral Health

Interventions

The study includes two test and one control group with a parallel design. The 3 patient groups consist of 60 patients, who initially will receive non-surgical periodontal treatment in two consecutive

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. 35 - 65 years-old 2. Presence of at least 16 teeth 3. Periodontitis with PD =5 mm with bleeding on probing (BOP) in at least 30% of the teeth

Exclusion criteria

Exclusion criteria: 1. Poorly controlled diabetes 2. Autoimmune diseases 3. Genetic disorders 4. Bone metabolic diseases 5. Bisphosphonate drugs 6. Drug-induced gingival overgrowth 7. Tumours or other oral pathology 8. Pregnant or lactating women 9. Antibiotic use for any purpose within 3 months before entering the study

Design outcomes

Primary

Measure	Time frame
Assessed before treatment initiation and at 6 weeks, 3-, 6- and 12 months post-treatment: PD, CAL, gingival recession (GR), full-mouth plaque scores (FMPS), full-mouth bleeding scores (FMBS), simplified gingival index (GI). All clinical measurements were taken using a manual probe. PD, CAL and GR were performed at six sites per tooth, while FMPS, GI and FMBS were recorded at four sites per tooth. Third molars were excluded from the measurements.	—

Measure

Time frame

Assessed before treatment initiation and at 6 weeks, 3-, 6- and 12 months post-treatment: PD, CAL, gingival recession (GR), full-mouth plaque scores (FMPS), full-mouth bleeding scores (FMBS), simplified gingival index (GI). All clinical measurements were taken using a manual probe. PD, CAL and GR were performed at six sites per tooth, while FMPS, GI and FMBS were recorded at four sites per tooth. Third molars were excluded from the measurements.

—

Secondary

Measure	Time frame
Immediately after treatment, sixty (60) questionnaire forms were provided to each subject. Patients were asked to fill out the questionnaire at the end of the first week of the completion of treatment. A visual analogue scale was used to assess patients’ perception of pain, sensitivity discomfort, swelling, bleeding and acceptance of the protocol during and after treatment. They were also asked to answer if they should suggest the treatment to a friend. This scale ranged from 0 to 10. Subjects marked a point on a 10-cm-long uncalibrated line with the negative extreme response (0) on the left end and the positive extreme response (10) at the right end. Additionally, the numbers of analgesic tablets taken were assessed.	—

Measure

Time frame

Immediately after treatment, sixty (60) questionnaire forms were provided to each subject. Patients were asked to fill out the questionnaire at the end of the first week of the completion of treatment. A visual analogue scale was used to assess patients’ perception of pain, sensitivity discomfort, swelling, bleeding and acceptance of the protocol during and after treatment. They were also asked to answer if they should suggest the treatment to a friend. This scale ranged from 0 to 10. Subjects marked a point on a 10-cm-long uncalibrated line with the negative extreme response (0) on the left end and the positive extreme response (10) at the right end. Additionally, the numbers of analgesic tablets taken were assessed.

—

Countries

Greece

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 12, 2026